Company intelligence / Profile preview

Dazane

Ownership: Private
Development stage: Other

Overview

Zhejiang Dazhan Biotechnology has established itself as a leading producer of high-end biopharmaceutical intermediates using advanced bioenzyme technology. Their processes enable greener, higher-purity synthesis of key drug precursors such as ATS‑4/ATS‑5 for atorvastatin and S‑3-hydroxytetrahydrofuran for empagliflozin. The company also manufactures coenzymes like NMN, NAD/NADP/NADH, PQQ, and adenosylmethionine at commercial scale. They operate GMP-compliant facilities with large-scale fermentation capacity.

Therapeutic areas: EndocrinologyCardiovascularOther
Modalities: Enzyme (Bioenzyme)Small molecule (pharmaceutical intermediates)Coenzyme
Industry: Chemicals & Materials

Partnerships

Long-term strategic partnerships with domestic and international pharma companies

Beyond the preview

Go deeper on Dazane.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dazane.

Explore the full profile